Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to ...

Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton ...

Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment ...

Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million in cash to gain access to its lead drug ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Acadia is seeing solid growth from its two products on the market. Check out the analysis of ACAD stock following Q4 numbers ...

We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be ...

Shuttle Pharmaceuticals Holdings announced the appointment of Christopher Cooper as interim Co-CEO focused on enhancing the Company’s capital markets and business capabilities.